Poseida Therapeutics, Inc. Poseida Therapeutics to Present Update on Approach in Allogeneic CAR-T at Society for Immunotherapy of Cancer 34th Annual Meeting November 5, 2019
Read More
NexImmune Inc. NexImmune Receives IND Clearance for Phase 1/2 trial in Acute Myeloid Leukemia / Myelodysplastic Syndrome ND clearance enables commencement of clinical trial to evaluate NEXI-001 in AML/MDS patients…
Poseida Therapeutics, Inc. Poseida Therapeutics Appoints Kerry Ingalls as Chief Operating Officer October 10, 2019
Rapha Capital and ControlRad, Inc. Rapha Capital Management Participates in Series B Financing for ControlRad, Inc. Led by Questa Capital October 2, 2019
ControlRad, Inc. ControlRad Announces First Clinical Use of ControlRad Trace Radiation Reduction Technology Niagara Falls Memorial Medical Center First to Integrate Newly Cleared ControlRad Trace into Fluoroscopically Guided Procedures, Improving…
Asclepix Therapeutics, Inc. AsclepiX Therapeutics Selected to Present at Ophthalmology Innovation Summit (OIS) at the American Society for Retinal Surgeons (ASRS) Annual Conference To Provide Update on AXT107 Duration of…
Bellicum Pharmaceuticals, Inc. Bellicum Pharmaceuticals Announces Rivo-cel™ Achieves Primary Endpoint in Pediatric Registrational Trial Primary endpoint of event free survival (EFS) rate at 180 days of 90.9 percent reported for…
Marker Therapeutics, Inc. Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma Data selected for oral presentation during a plenary session…
Control Rad™ ControlRad™ Announces FDA Clearance and Launch of the Only Radiation Reduction Technology that Integrates into Mobile C-arms May 22, 2019
Poseida Therapeutics Poseida Therapeutics Receives US FDA Orphan Drug Designation for P-BCMA-101 for the Treatment of Multiple Myeloma May 13, 2019